Chest X-Rays May Miss Pulmonary Metastases in T1a RCC Patients
Findings in patients treated for T1a renal cell carcinoma followed with X-ray surveillance.
Findings in patients treated for T1a renal cell carcinoma followed with X-ray surveillance.
The drug significantly improves overall and progression-free survival compared with everolimus, researchers report.
The optimal tumor shrinkage threshold for predicting overall and progression-free survival is 10%, researchers concluded.
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.
Only this histologic variant occurs at a significantly higher incidence in renal allograft recipients than the non-transplant population.
Cytoreductive nephrectomy (CN) use remained stable in the targeted therapy era, but more patients are receiving a combination of CN and systemic therapy.
Study shows no meaningful differences between partial and radical nephrectomy in 5-year rates of local recurrence or cancer-related death.
Positive surgical margins are associated with a significant 34% increased risk of all-cause mortality.